

Disclaimer :

The Competition DG makes the information provided by the notifying parties in section 1.2 of Form CO available to the public in order to increase transparency. This information has been prepared by the notifying parties under their sole responsibility, and its content in no way prejudices the view the Commission may take of the planned operation. Nor can the Commission be held responsible for any incorrect or misleading information contained therein.

M.8937 - ADVENT INTERNATIONAL / ZENTIVA

SECTION 1.2

Description of the concentration

On 8 June 2018, the Commission received a notification of a proposed concentration pursuant to which Advent International Corporation (*Advent*) would acquire sole control over pharmaceutical generics group *Zentiva*.

Advent is a global private equity investor: the firm focuses on investments in five core sectors, namely business and financial services; healthcare; industrial; retail, consumer and leisure; and technology, media and telecom. In the area of pharmaceuticals, Advent currently controls two companies that operate however exclusively outside the EEA.

Zentiva is a pharmaceutical group focused on the development, manufacturing and marketing of generic pharmaceutical products primarily within Europe.